Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in Metastatic Castration-Resistant Prostate Carcinoma
NCT02113657Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2014
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in prostate carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Impact of Ipilimumab on T Cell Responses to prostate cancer neoantigens at 10 weeks. Started Aug 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
prostate carcinoma
Beyond the preview
Go deeper on NCT02113657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113657.